ONWARD Medical Reports First Quarter 2026 Results
ONWARD Medical NV reported strong commercial momentum in Q1 2026, highlighting the success of their ARC-EX system for spinal cord injury rehabilitation and the advancement of their clinical trials, including the Empower BP study for blood pressure management. The company raised EUR 40 million to support further development and expansion, reporting a total revenue of EUR 2.0 million for the quarter.
EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the first quarter of 2026:
